We Are Crinetics

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Read the Latest

Crinetics Pharmaceuticals Provides Update on CRN04777 Program

Crinetics provided an update on development of CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism

Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Crinetics management will participate in a fireside chat on November 30, 2022 at the 5th Annual Evercore ISI HealthCONx Conference